Redx Pharma (REDX) Sets New 12-Month Low at $17.00

Shares of Redx Pharma PLC (LON:REDX) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 17 ($0.23) and last traded at GBX 18 ($0.24), with a volume of 59993 shares trading hands. The stock had previously closed at GBX 18 ($0.24).

The firm has a market capitalization of $19.02 and a PE ratio of -1,750.00.

In other news, insider Iain Ross bought 348,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was acquired at an average cost of GBX 18 ($0.24) per share, for a total transaction of £62,640 ($84,947.11).

WARNING: “Redx Pharma (REDX) Sets New 12-Month Low at $17.00” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/redx-pharma-redx-sets-new-12-month-low-at-17-00.html.

About Redx Pharma

Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton’s Tyrosine Kinase (BTK), which has reached candidate nomination stage.

Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply